Launch of the European NISCI Study on Regeneration of the Injured Spinal Cord in People with Tetraplegia
Under the direction of Profs. Martin Schwab and Armin Curt of the University of Zurich, the European multicentre clinical study NISCI (Nogo Inhibition in Spinal Cord Injury) has been launched in Switzerland. The study is investigating the effect of NOGO antibody therapy on nerve fibre regeneration and functional recovery following an acute spinal cord injury in the cervical region. Several clinics in Switzerland and five other European countries are participating in the study.

More than 30 years ago, neuroscientist Prof. Dr. Martin Schwab (IRP Research Council member and Vice-President from 1996 to 2019) at the University of Zurich began investigating why nerve fibres in the spinal cord and brain do not heal again after an injury. Using anatomical and behavioural experiments, he was able to demonstrate that a protein called NOGO, found in the sheaths surrounding nerve fibres, is responsible for preventing damaged fibres from growing back, or regenerating.
The discovery of the nerve growth inhibitor NOGO laid an important foundation for the development of a drug that could improve the recovery process.
Martin Schwab pursued a biological approach: the active substance was intended to inactivate the NOGO protein, thereby stimulating the growth and regeneration of nerve fibres and allowing functions lost as a result of the injury to be restored. An antibody that specifically recognises NOGO, binds to it and thus blocks its natural function was therefore the treatment of choice. The use of the NOGO antibody in animal experiments impressively demonstrated that nerve regeneration after spinal cord injury could be stimulated and lost motor functions could be restored.
These groundbreaking results inspired not only basic researcher Martin Schwab, but also clinical colleagues at spinal cord injury centres and the pharmaceutical industry. This led to many years of collaboration between Martin Schwab, the Swiss pharmaceutical company Novartis and the European clinical network EMSCI, supported by IRP and led by Prof. Armin Curt, Head of the Spinal Cord Injury Centre at Balgrist University Hospital in Zurich. A NOGO antibody was developed that met the strict quality requirements of the Swiss medicines regulatory authority, SWISSMEDIC. This made it possible to conduct a Europe-wide Phase I clinical trial of NOGO antibodies involving 52 patients with recent spinal cord injuries. The aim of this study was to determine the optimal dosage of the active substance in humans and to investigate potential side effects. The results of the study were consistently positive, providing the necessary basis for a subsequent Phase II efficacy study.
Martin Schwab and his clinical colleagues developed a strategy to enable a researcher-initiated efficacy study. Their plan was successful, and the EU Horizon 2020 programme provided the financial resources required to cover the costs of the clinical trials. ‘Wyss Zurich’, the translational research centre of ETH Zurich and the University of Zurich, also supports the NOGO project as the manufacturer of the antibody with several million Swiss francs. In addition to financial support, the expertise of the Wyss Zurich team and its regenerative medicine platform was essential in successfully guiding the NOGO project through the complex regulatory requirements.
And the efforts have paid off: the NOGO project has received approval to launch the NISCI study in Switzerland. Approval from the German authorities is expected in summer 2019. In a subsequent step, approvals will be sought in Italy, Spain and the Czech Republic so that people affected by spinal cord injuries in these countries can also be included in the NOGO study.
Overall, the NOGO study is planned to run for a period of three to four years. This duration is necessary to examine a sufficient number of patients and ultimately draw clear conclusions about the effectiveness of the antibody. The results are already being awaited with great interest and anticipation by both those affected and the scientific community.
